N4 Pharma Plc’s Post

Are you attending the upcoming #Immuno24 Meeting on April 25 in London? If so, Sylwia Marshall, our Head of Translational Science, will be presenting about optimising and selecting the right doses in clinical trials. Please catch her keynote address to learn more about this important topic in clinical development. #OGImmuno #immunooncology #biotech #clinicaltrials

In pursuing clinical research innovation, smaller biopharma companies often face a different set of challenges than larger pharma. Lacking the extensive resources and unique personnel functions of large pharmaceutical organizations, they must navigate tighter budgets and limited staffing. Yet, precisely, those constraints are what push many small biopharma to be more agile, inventive, and resilient. On May 20th at 12pm EST, join ProofPilot and Yonalink as we hear these stories of resilience, inventiveness, and agility firsthand. I can't express enough gratitude to these three leading women in biopharma for sharing their stories of derisking innovation to compete with powerhouse pharma teams: ▶ Erin O'Boyle, VP of Clinical Operations at Rezolute, Inc. ▶ Joann Peters, COO at Geneos Therapeutics ▶ Meraf Eyassu, Executive Director of Clinical Operations at Terns Pharmaceuticals Registration is in the links! 👇

Check out the latest roundtable with Pharma's Almanac and hear from Lexitas CEO Jeanne Hecht and other industry leaders as they discuss how advancements in technology are reshaping the roles and capabilities of CDMOs and CROs. https://lnkd.in/gVyTWxE3 #clinicalresearch #CRO #ophthalmology #innovation #technology #Lexitas

🔎 Have ONO PHARMACEUTICAL CO., LTD. found the next best target? 🤝 Last week we saw Ono Pharmaceutical combine forces with LigaChem Biosciences in a deal of up to $700 million, driving progress of first-in-class solid tumour candidate LCB97. 📈 This exciting release has caught the eye of many, opening the door to a potential new avenue of ADC targets, with LCB97 being the first of it’s kind targeting cells expressing L1CAM. Is this new ADC target destined for clinical success? 💡 In a congested ADC field, the ever-growing landscape of biopharma and biotech are now allocating significant resources into selecting novel targets for ADCs, adopting a first-in-class approach to development, embarking on a mission to find that golden nugget to break through the noise in this booming field. 🎫 The 4th ADC Target Selection Summit is uniquely positioned at the home of such discussion, fostering discussion around both strategic and technical considerations when identifying and validating novel targets which can be efficacious in ADC drug delivery. 📜 View the full agenda for the summit here – https://ter.li/6jkh9q 💫 Join Oxford BioTherapeutics, AbbVie, Bristol Myers Squibb, GO Therapeutics and many more who will be touching down in San Diego this December to outline target selection strategy, including discussion around artificial intelligence, bispecific targets, expression dynamics and more. 📥 If you have any questions at all regarding the summit, please do not hesitate to reach out, my inbox is always open! #adc #antibody #drug #conjugate #target #novel Iwan Cleave Ella Broome Karim Hoceine

📣 New insights from our R&D Productivity and Growth RankingReport as we enter #Q4 2024!🚀 🎉 Jazz Pharmaceuticals has made a remarkable entry into the Top 10 for R&D Productivity, showcasing impressive strides in innovation and development.  🔍 Dive into the full report for insights on how leading biopharma / biotech companies are performing and driving growth. 🔗Link to the full report as below 💬 What are your thoughts on these rankings? How do you see the future of biopharma R&D evolving? #Biopharma #RDProductivity #Innovation #PharmaTrends #Biotech #HealthcareInnovation #IndustryInsights #GlobalRanking

📣 Our portfolio company Kither Biotech, active in #CysticFibrosis and other respiratory indications, announced today the start of a Phase 1 clinical study. 👏 Congratulations to the CEO Dimitrios Goundis, to Prof. Alessandra Ghigo, Prof. Emilio Hirsch, Marco Kevin Malisani, Carla Uslenghi, Valentina Sala and the whole team – it has been an amazing journey so far for Ciro Spedaliere and myself, and it is extremely rewarding being now able to move our lead program into the clinic, especially being the company based in our home-town #Turin. This is the third product that Claris Ventures portfolio companies are progressing into clinical studies over the last year. Pursing better cures is our primary objective, and value will follow - no doubts – once we will deliver on this ambitious and important goal. Last but not least, on Monday Resalis Therapeutics announced a strategic investment received from Sanofi, just a few months after another pharmaceutical company (BMS) had invested into our portfolio company NeoPhore Ltd. 😉 All in all, this stands as a very important week for Claris Ventures and it pushes us to do more and more to scale the ambitions and means of our portfolio companies. We recognize how lucky we are to work with amazing teams and to be involved frontline in the progress that our companies are making. #biotech #vc #clinicaldevelopment #clinicaltrial https://lnkd.in/dh5PEyxV

Another strong performance for AstraZeneca who continue to thrive in the pharma innovation and invention space, ranking 7th on the Innovation Index and 3rd on the Invention Index. They achieved significant regulatory milestones, including three first NME approvals, 17 NMEs in late-stage development, and 123 NME or major LCM projects in Phase 2 or 3. Key approvals include among others: Airsupra (albuterol/budesonide), an as-needed treatment to reduce risk of asthma exacerbations; Truqap (capivasertib), a first-in-class AKT inhibitor for certain breast cancer indications with one or more biomarker alterations; and Wainua (eplontersen), the only approved self-administered auto-injector for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. See the full analysis at - www.ideapharma.com/pii #pharmaceutical #innovation #PIII2024

Key insights - tks to Anne Dhulesia - on the BD&L strategy of Pharma companies to access I&O innovation.

Insights from Day Three of the BIO International Convention in San Diego: https://ow.ly/ekkY50SkhuO. Included in this installment of Scrip’s daily notebook of noteworthy intelligence from the BIO International Convention: • Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act" • Novo Nordisk's business development head discussing spending its semaglutide bounty • Roivant Sciences's long view on BD prospects for Immunovant's FcRn inhibitor • More regulatory concerns around artificial intelligence #ArtificialIntelligence #InnovationReductionAct #Pharma #Biotech #BIOInternationalConvention

Recent FDA approvals for new drugs targeting complement proteins means there has never been greater momentum than now in the development of new complement therapeutics. At Kypha we have long recognized how much potential remains untapped in the complement space. With our expertise in measuring these molecules and our purpose-built complement biomarker platform, we are well positioned to help small biotech and large pharma capitalize on this renewed focus on the complement pathway. To find out more about our complement expertise, visit https://lnkd.in/eXvm62xD #complement #complementdiagnostics #complementtherapeutics #immunemonitoring #diagnostics #immunediagnostics